567 related articles for article (PubMed ID: 20823087)
1. Relationship of dementia screening tests with biomarkers of Alzheimer's disease.
Galvin JE; Fagan AM; Holtzman DM; Mintun MA; Morris JC
Brain; 2010 Nov; 133(11):3290-300. PubMed ID: 20823087
[TBL] [Abstract][Full Text] [Related]
2. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
[TBL] [Abstract][Full Text] [Related]
3. Pittsburgh compound B imaging and cerebrospinal fluid amyloid-β in a multicentre European memory clinic study.
Leuzy A; Chiotis K; Hasselbalch SG; Rinne JO; de Mendonça A; Otto M; Lleó A; Castelo-Branco M; Santana I; Johansson J; Anderl-Straub S; von Arnim CA; Beer A; Blesa R; Fortea J; Herukka SK; Portelius E; Pannee J; Zetterberg H; Blennow K; Nordberg A
Brain; 2016 Sep; 139(Pt 9):2540-53. PubMed ID: 27401520
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia.
Skillbäck T; Farahmand BY; Rosén C; Mattsson N; Nägga K; Kilander L; Religa D; Wimo A; Winblad B; Schott JM; Blennow K; Eriksdotter M; Zetterberg H
Brain; 2015 Sep; 138(Pt 9):2716-31. PubMed ID: 26133663
[TBL] [Abstract][Full Text] [Related]
5. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.
Mattsson N; Insel PS; Donohue M; Landau S; Jagust WJ; Shaw LM; Trojanowski JQ; Zetterberg H; Blennow K; Weiner MW;
Brain; 2015 Mar; 138(Pt 3):772-83. PubMed ID: 25541191
[TBL] [Abstract][Full Text] [Related]
6. Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid.
Rosenberg A; Solomon A; Jelic V; Hagman G; Bogdanovic N; Kivipelto M
Alzheimers Res Ther; 2019 Dec; 11(1):99. PubMed ID: 31805990
[TBL] [Abstract][Full Text] [Related]
7. Comparative Performance and Neuropathologic Validation of the AD8 Dementia Screening Instrument.
Morris GM; Holden TR; Weng H; Xiong C; Coble DW; Cairns NJ; Morris JC
Alzheimer Dis Assoc Disord; 2020; 34(2):112-117. PubMed ID: 31725472
[TBL] [Abstract][Full Text] [Related]
8. The Latent Dementia Phenotype δ is Associated with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Predicts Conversion to Dementia in Subjects with Mild Cognitive Impairment.
Koppara A; Wolfsgruber S; Kleineidam L; Schmidtke K; Frölich L; Kurz A; Schulz S; Hampel H; Heuser I; Peters O; Reischies FM; Jahn H; Luckhaus C; Hüll M; Gertz HJ; Schröder J; Pantel J; Rienhoff O; Rüther E; Henn F; Wiltfang J; Maier W; Jessen F; Kornhuber J; Wagner M
J Alzheimers Dis; 2016; 49(2):547-60. PubMed ID: 26484902
[TBL] [Abstract][Full Text] [Related]
9. High performance plasma amyloid-β biomarkers for Alzheimer's disease.
Nakamura A; Kaneko N; Villemagne VL; Kato T; Doecke J; Doré V; Fowler C; Li QX; Martins R; Rowe C; Tomita T; Matsuzaki K; Ishii K; Ishii K; Arahata Y; Iwamoto S; Ito K; Tanaka K; Masters CL; Yanagisawa K
Nature; 2018 Feb; 554(7691):249-254. PubMed ID: 29420472
[TBL] [Abstract][Full Text] [Related]
10. Comparisons of clinical symptoms in biomarker-confirmed Alzheimer's disease, dementia with Lewy bodies, and frontotemporal dementia patients in a local memory clinic.
Shea YF; Ha J; Chu LW
Psychogeriatrics; 2015 Dec; 15(4):235-41. PubMed ID: 25533477
[TBL] [Abstract][Full Text] [Related]
11. Comparison of 2 informant questionnaire screening tools for dementia and mild cognitive impairment: AD8 and IQCODE.
Razavi M; Tolea MI; Margrett J; Martin P; Oakland A; Tscholl DW; Ghods S; Mina M; Galvin JE
Alzheimer Dis Assoc Disord; 2014; 28(2):156-61. PubMed ID: 24113559
[TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal Fluid C18 Ceramide Associates with Markers of Alzheimer's Disease and Inflammation at the Pre- and Early Stages of Dementia.
Teitsdottir UD; Halldorsson S; Rolfsson O; Lund SH; Jonsdottir MK; Snaedal J; Petersen PH
J Alzheimers Dis; 2021; 81(1):231-244. PubMed ID: 33814423
[TBL] [Abstract][Full Text] [Related]
13. Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.
Susanto TA; Pua EP; Zhou J;
J Alzheimers Dis; 2015; 45(1):253-68. PubMed ID: 25524955
[TBL] [Abstract][Full Text] [Related]
14. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum.
Murray ME; Lowe VJ; Graff-Radford NR; Liesinger AM; Cannon A; Przybelski SA; Rawal B; Parisi JE; Petersen RC; Kantarci K; Ross OA; Duara R; Knopman DS; Jack CR; Dickson DW
Brain; 2015 May; 138(Pt 5):1370-81. PubMed ID: 25805643
[TBL] [Abstract][Full Text] [Related]
16. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
[TBL] [Abstract][Full Text] [Related]
17. Memory Correlates of Alzheimer's Disease Cerebrospinal Fluid Markers: A Longitudinal Cohort Study.
Reijs BLR; Ramakers IHGB; Köhler S; Teunissen CE; Koel-Simmelink M; Nathan PJ; Tsolaki M; Wahlund LO; Waldemar G; Hausner L; Vandenberghe R; Johannsen P; Blackwell A; Vanderstichele H; Verhey F; Visser PJ
J Alzheimers Dis; 2017; 60(3):1119-1128. PubMed ID: 28984585
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
[TBL] [Abstract][Full Text] [Related]
19. Educational effects on ascertain dementia 8-item informant questionnaire to detect dementia in the Taiwanese population.
Chen SF; Liu MH; Chen NC; Horng HD; Tsao WL; Chang CC; Chang YT
Int Psychogeriatr; 2018 Aug; 30(8):1189-1197. PubMed ID: 29223190
[TBL] [Abstract][Full Text] [Related]
20. Neuropsychological Decline Improves Prediction of Dementia Beyond Alzheimer's Disease Biomarker and Mild Cognitive Impairment Diagnoses.
Nation DA; Ho JK; Dutt S; Han SD; Lai MHC;
J Alzheimers Dis; 2019; 69(4):1171-1182. PubMed ID: 31104015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]